New therapies for castrate-resistant prostate cancer

Stephen B. Williams; Aaron H. Lay; Clayton S. Lau; David Y. Josephson; Timothy G. Wilson; Toni K. Choueiri; Sumanta K. Pal

doi:10.1517/14656566.2011.590133

New therapies for castrate-resistant prostate cancer

Stephen B. Williams, Aaron H. Lay, Clayton S. Lau, David Y. Josephson, Timothy G. Wilson, Toni K. Choueiri, Sumanta K. Pal

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Prostate cancer is the second leading cause of cancer death in men in the USA, and most of these deaths will occur as a result of castrate-resistant prostate cancer (CRPC) that has progressed despite androgen deprivation therapy. There has been better understanding of castration resistance and molecular mechanisms of prostate cancer progression recently, leading to new treatment strategies. Areas covered: This review focuses on emerging and new therapies for castrate-resistant prostate cancer, including hormonal therapy, immunotherapy and cytotoxic agents. Expert opinion: New treatment strategies have been developed in recent years and, with improved understanding of advanced CRPC, additional targeted treatments are expected in the near future. Further cost effectiveness research of these treatments is warranted before dissemination of these promising agents.

Original language	English (US)
Pages (from-to)	2069-2074
Number of pages	6
Journal	Expert Opinion on Pharmacotherapy
Volume	12
Issue number	13
DOIs	https://doi.org/10.1517/14656566.2011.590133
State	Published - Sep 2011
Externally published	Yes

Keywords

castrate resistant
chemotherapy
outcomes
prostate cancer
review

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1517/14656566.2011.590133

Cite this

@article{756ddf0a97754994927ab41fec67a461,

title = "New therapies for castrate-resistant prostate cancer",

abstract = "Prostate cancer is the second leading cause of cancer death in men in the USA, and most of these deaths will occur as a result of castrate-resistant prostate cancer (CRPC) that has progressed despite androgen deprivation therapy. There has been better understanding of castration resistance and molecular mechanisms of prostate cancer progression recently, leading to new treatment strategies. Areas covered: This review focuses on emerging and new therapies for castrate-resistant prostate cancer, including hormonal therapy, immunotherapy and cytotoxic agents. Expert opinion: New treatment strategies have been developed in recent years and, with improved understanding of advanced CRPC, additional targeted treatments are expected in the near future. Further cost effectiveness research of these treatments is warranted before dissemination of these promising agents.",

keywords = "castrate resistant, chemotherapy, outcomes, prostate cancer, review",

author = "Williams, {Stephen B.} and Lay, {Aaron H.} and Lau, {Clayton S.} and Josephson, {David Y.} and Wilson, {Timothy G.} and Choueiri, {Toni K.} and Pal, {Sumanta K.}",

year = "2011",

month = sep,

doi = "10.1517/14656566.2011.590133",

language = "English (US)",

volume = "12",

pages = "2069--2074",

journal = "Expert Opinion on Pharmacotherapy",

issn = "1465-6566",

publisher = "Informa Healthcare",

number = "13",

}

TY - JOUR

T1 - New therapies for castrate-resistant prostate cancer

AU - Williams, Stephen B.

AU - Lay, Aaron H.

AU - Lau, Clayton S.

AU - Josephson, David Y.

AU - Wilson, Timothy G.

AU - Choueiri, Toni K.

AU - Pal, Sumanta K.

PY - 2011/9

Y1 - 2011/9

N2 - Prostate cancer is the second leading cause of cancer death in men in the USA, and most of these deaths will occur as a result of castrate-resistant prostate cancer (CRPC) that has progressed despite androgen deprivation therapy. There has been better understanding of castration resistance and molecular mechanisms of prostate cancer progression recently, leading to new treatment strategies. Areas covered: This review focuses on emerging and new therapies for castrate-resistant prostate cancer, including hormonal therapy, immunotherapy and cytotoxic agents. Expert opinion: New treatment strategies have been developed in recent years and, with improved understanding of advanced CRPC, additional targeted treatments are expected in the near future. Further cost effectiveness research of these treatments is warranted before dissemination of these promising agents.

AB - Prostate cancer is the second leading cause of cancer death in men in the USA, and most of these deaths will occur as a result of castrate-resistant prostate cancer (CRPC) that has progressed despite androgen deprivation therapy. There has been better understanding of castration resistance and molecular mechanisms of prostate cancer progression recently, leading to new treatment strategies. Areas covered: This review focuses on emerging and new therapies for castrate-resistant prostate cancer, including hormonal therapy, immunotherapy and cytotoxic agents. Expert opinion: New treatment strategies have been developed in recent years and, with improved understanding of advanced CRPC, additional targeted treatments are expected in the near future. Further cost effectiveness research of these treatments is warranted before dissemination of these promising agents.

KW - castrate resistant

KW - chemotherapy

KW - outcomes

KW - prostate cancer

KW - review

UR - http://www.scopus.com/inward/record.url?scp=80051537020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051537020&partnerID=8YFLogxK

U2 - 10.1517/14656566.2011.590133

DO - 10.1517/14656566.2011.590133

M3 - Review article

C2 - 21663529

AN - SCOPUS:80051537020

SN - 1465-6566

VL - 12

SP - 2069

EP - 2074

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

IS - 13

ER -

New therapies for castrate-resistant prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this